What is the Future Position of Factor XIa Inhibitors for Patients with Atrial Fibrillation?-Reference-Cited by-同舟云学术

What is the Future Position of Factor XIa Inhibitors for Patients with Atrial Fibrillation?

Published:2024-07-01 Issue: Volume:19 Page:
ISSN:1758-3764
Container-title:European Cardiology Review
language:en
Short-container-title:Eur Cardiol

Author:

Komiyama Maki¹^ORCID,Iguchi Moritake²^ORCID,Wada Hiromichi¹^ORCID,Ikeda Takanori³^ORCID,Dan Gheorghe-Andrei⁴^ORCID,Hasegawa Koji¹^ORCID

Affiliation:

1. Division of Translational Research, NHO Kyoto Medical Centre, Kyoto, Japan

2. Department of Cardiac Rehabilitation, NHO Kyoto Medical Centre, Kyoto, Japan

3. Department of Cardiovascular Medicine, Toho University Faculty of Medicine, Tokyo, Japan

4. Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; Romanian Academy of Scientists, Bucharest, Romania

Abstract

Factor XIa (FXIa) may be involved in thrombus formation, but only to a lesser extent involved in haemostasis. Several novel FXIa inhibitors are under investigation, and Phase II trials demonstrated marked reduction of bleeding compared with standard treatment by factor Xa inhibitors. Asundexian is a small molecule that selectively inhibits FXIa. A large-scale Phase III clinical trial, OCEANIC-AF, has been initiated to compare the efficacy and safety between asundexian and apixaban. However, the OCEANIC-AF study was recently halted due to the inferior efficacy of asundexian versus the apixaban control arm. The present report describes up-to-date evidence of FXIa inhibitors and discusses the future position of FXIa inhibitors for patients with AF.

Publisher

Radcliffe Media Media Ltd

Reference7 articles.

1. Weitz JI, Strony J, Ageno W, et al. Milvexian for the prevention of venous thromboembolism. N Engl J Med 2021;385:2161–72. https://doi.org/10.1056/NEJMoa2113194; PMID: 34780683.

2. Hasegawa K, Ikeda T. Pharmapulse report-does the arrival of factor XI inhibitors mark the end of the NOAC era? Eur Heart J Cardiovasc Pharmacother 2022;8:E9. https://doi.org/10.1093/ehjcvp/pvac003; PMID: 35088076.

3. Piccini JP, Caso V, Connolly SJ, et al. Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. Lancet 2022;399:1383–90. https://doi.org/10.1016/S0140-6736(22)00456-1; PMID: 35385695.

4. Bahit MC, Lopes RD, Wojdyla DM, et al. Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation. Heart 2017;103:623–8. https://doi.org/10.1136/heartjnl-2016-309901; PMID: 27798052.

5. Ruff CT. AZALEA-TIMI 71: a multicenter, randomized, active-controlled study to evaluate the safety and tolerability of two blinded doses of abelacimab compared with open-label rivaroxaban in patients with atrial fibrillation. Presented at: American Heart Association Scientific Sessions, Philadelphia, PA, US, 11 November 2023.